Use of Rh immune globulin: ASCP practice parameter

American Journal of Clinical Pathology

Volumn 110, Issue 3, 1998, Pages 281-292

  Hartwell, Elizabeth A ^a  

^a NONE

Author keywords

Fetomaternal hemorrhage; Guideline; Hemolytic disease of the newborn; Practice parameter; Rh immune globulin; RhIG

Indexed keywords

RHESUS ANTIBODY;

ADULT; AMNIOCENTESIS; ARTICLE; BLOOD TRANSFUSION; DRUG CONTRAINDICATION; ECTOPIC PREGNANCY; FETUS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPROPHYLAXIS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEWBORN; NEWBORN HEMOLYTIC DISEASE; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PREGNANCY TERMINATION; PRENATAL CARE; PRIORITY JOURNAL; RHESUS IMMUNIZATION; TREATMENT INDICATION; UTERINE TUBE LIGATION;

EID: 0031784396     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/110.3.281     Document Type: Article

References (90)

1. Bergstrom H, Nilsson LA, Nilsson L, et al. Demonstration of Rh antigens in a 38-day-old fetus. Am J Obstet Gynecol. 1967;99:130-133.
2. Bowman JM. Hemolytic disease (erythroblastosis fetalis). In: Creasy RK, Resnik R, eds. Maternal-Fetal Medicine: Principles and Practice. 3rd ed. Philadelphia, Pa: Saunders; 1994:711-743.
3. Zipursky A, Israels LG. The pathogenesis and prevention of Rh immunization. Can Med Assoc J. 1967;97:1245-1257.
4. Bowman JM, Pollock JM, Penston LE. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sang. 1986;51:117-121.
5. Cohen F, Zuelzer WW, Gustafson DC, et al. Mechanisms of isoimmunization, I: the transplacental passage of fetal erythrocytes in homospecific pregnancies. Blood. 1964;23:621-646.
6. Levine P, Vogel P, Katzin EM, et al. Pathogenesis of erythroblastosis fetalis: statistical evidence. Science. 1941;94:371-372.
7. 2-globulin antibody preparation: a preliminary report. Transfusion. 1964;4:26-32.
8. Clarke CA, Donohoe WTA, McConnell RB, et al. Further experimental studies on the prevention of Rh haemolytic disease. BMJ. 1963;1:979-984.
9. Pollack W, Gorman JG, Freda VJ, et al. Results of clinical trials of RhoGAM in women. Transfusion. 1968;8:151-153.
10. McMaster Conference on Prevention of Rh Immunization. Vox Sang. 1979;36:50-64.
11. Scott JR, Beer AE, Guy LR, et al. Pathogenesis of Rh immunization in primigravidas. Obstet Gynecol. 1977;49:9-14.
12. Bowman JM, Chown B, Lewis M, et al. Rh isoimmunization during pregnancy: antenatal prophylaxis. Can Med Assoc J. 1978;118:623-627.
13. American College of Obstetricians and Gynecologists. The Selective Use of Rho(D) Immune Globulin (RhIG). Washington, DC: American College of Obstetricians and Gynecologists; 1981. Technical Bulletin 61.
14. American College of Obstetricians and Gynecologists. Prevention of Rho(D) Isoimmunization. Washington, DC: American College of Obstetricians and Gynecologists; 1984. Technical Bulletin 79.
15. American College of Obstetricians and Gynecologists. Prevention of D Isoimmunization. Washington, DC: American College of Obstetricians and Gynecologists; 1990. Technical Bulletin 147.
16. Centers for Disease Control. Lack of transmission of human immunodeficiency virus through Rho(D) immune globulin (human). MMWR Morbid Mortal Wkly Rep. 1987;36: 728-729.
17. Power JP, Lawlor E, Davidson F, et al. Hepatitis C viraemia in recipients of Irish intravenous anti-D immunoglobulin. Lancet. 1994;344:1166-1167.
18. Contreras M, de Silva M. The prevention and management of haemolytic disease of the newborn. J R Soc Med. 1994; 87:256-258.
19. Moulds JJ. Immunosuppression by passive antibody. In: Bell CA, ed. A Seminar on Perinatal Blood Banking. Washington, DC: American Association of Blood Banks; 1978:77-92.
20. Pollack W, Ascari WQ, Kochesky RJ, et al. Studies on Rh prophylaxis: relationship between doses of anti-Rh and size of antigenic stimulus. Transfusion. 1971;11:333-339.
21. Vengelen-Tyler V, ed. Technical Manual. 12th ed. Bethesda, Md: American Association of Blood Banks; 1996.
22. ® [package insert]. Winnipeg, Manitoba: Cangene; 1997.
23. Bowman JM. Preventing Rh sensitization during pregnancy. Perinatal Care. 1978;2:24-32.
24. Tabsh KMA, Lebherz TB, Crandall BF. Risks of prophylactic anti-D immunoglobulin after second-trimester amniocentesis. Am J Obstet Gynecol. 1984;150:225-226.
25. Hensleigh PA. Preventing rhesus isoimmunization: antepartum Rh immune globulin prophylaxis versus a sensitive test for risk identification. Am J Obstet Gynecol. 1983;146:749-755.
26. Thorton JG, Page C, Foote G, et al. Efficacy and long term effects of antenatal prophylaxis with anti-D immunoglobulin. BMJ. 1989;298:1671-1673.
27. Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmunization: 28-weeks'-gestation service program. Can Med Assoc J. 1978;118:627-630.
28. Kramer MJ. Point of view. Perinatal Care. 1978;2:56.
29. Bowman JM. Suppression of Rh isoimmunization: a review. J Obstet Gynecol. 1978;52:385-393.
30. Klein HG, ed. Standards for Blood Banks and Transfusion Services. 17th ed. Bethesda, Md: American Association of Blood Banks; 1996.
31. Samson D, Mollison PL. Effect on primary Rh immunization of delayed administration of anti-Rh. Immunology. 1975;28:349-357.
32. Litwak O, Taswell HF, Banner EA, et al. Fetal erythrocytes in maternal circulation after spontaneous abortion. JAMA. 1970;214:531-534.
33. Freda VJ, Gorman JG, Galen RS, et al. The threat of Rh immunization by abortion. Lancet. 1970;2:147-148.
34. Kochenour NK, Beeson JH. The use of Rh-immune globulin. Clin of Obstet Gynecol. 1982;25:283-291.
35. Judelsohn RG, Berger GS, Wallace RB, et al. Rh-immune globulin in induced abortion: utilization in a high-risk population. Am J Obstet Gynecol. 1972;114:1031-1034.
36. Katz J, Marcus RG. The risk of Rh isoimmunization in ruptured tubal pregnancy. BMJ. 1972;3:667-669.
37. Aborjaily AN. Rh sensitization after tubal pregnancy. New Engl J Med. 1969;281:1076. Letter.
38. van't Veer MB, Overbeeke MAM, Geertzen HGM, et al. The expression of Rh-D factor in human trophoblast. Am J Obstet Gynecol. 1984;150:1008-1010.
39. Keith L, Bozorgi N. Small dose anti-Rh therapy after first trimester abortion. Int J Gynaecol Obstet. 1977;15:235-237.
40. Bowman JM, Pollock JM. Transplacental fetal hemorrhage after amniocentesis. Obstet Gynecol. 1985;66:749-754.
41. Hill LM, Platt LD, Kellogg B. Rh sensitization after genetic amniocentesis. Obstet Gynecol. 1980;56:459-461.
42. Bowman JM. Controversies in Rh prophylaxis: who needs Rh immune globulin and when should it be given? Am J Obstet Gynecol. 1985;151:289-294.
43. Bowman JM, Pollock JM, Peterson LE, et al. Fetomaternal hemorrhage following funipuncture: increase in severity of maternal red-cell alloimmunization. Obstet Gynecol. 1994;84:839-843.
44. Rose PG, Strohm PL, Zuspan FP. Fetomaternal hemorrhage following trauma. Am J Obstet Gynecol. 1985;153:844-847.
45. Pearlman MD, Tintinalli JE, Lorenz RP. A prospective controlled study of outcome after trauma during pregnancy. Am J Obstet Gynecol. 1990;162:1502-1510.
46. Pearlman MD, Tintianlli JE, Lorenz RP. Blunt trauma during pregnancy. New Engl J Med. 1990;323:1609-1613.
47. Gorman JG, Freda VJ. Rh immune globulin is indicated for Rh-negative mothers undergoing sterilization. Am J Obstet Gynecol. 1972;112:868-569.
48. Chi I, Jones DB. Incidence, risk factors, and prevention of poststerilization regret in women: an updated international review from an epidemiological perspective. Obstet Gynecol Surv. 1994;49:722-732.
49. Kawachi I, Colditz GA, Hankinson S. Long-term benefits and risks of alternative methods of fertility control in the United States. Contraception. 1994;50:1-16.
50. Keith L. Anti-Rh therapy after transfusion. J Reprod Med. 1972;8:293-298.
51. Pollack W, Ascari WQ, Crispen JF, et al. Studies on Rh prophylaxis: Rh immune prophylaxis after transfusion with Rh-positive blood. Transfusion. 1971;11:340-344.
52. Graham EM, Freedman LJ, Forouzan I, et al. Prevention of Rh isoimmunization after spontaneous, massive fetomaternal hemorrhage. South Med J. 1996;89:911-914.
53. Mollison PL, Engelfriet CP, Contreras M, eds. Blood Transfusion in Clinical Medicine. 9th ed. Boston, Mass: Blackwell Scientific Publications; 1993:241-245.
54. Bussel JB, Graziano JN, Kimberly RP, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood. 1991;9: 1884-1893.
55. Scaradavou A, Woo B, Woloski BMR, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997;89:2689-2700.
56. Judd WJ, Luban NLC, Ness PM, et al. Prenatal and perinatal immunohematology: recommendations for serologic management of the fetus, newborn infant, and obstetric patient. Transfusion. 1990;30:175-183.
57. Mollison PL, Engelfriet CP, Contreras M, eds. Blood Transfusion in Clinical Medicine. 9th ed. Boston, Mass: Blackwell Scientific Publications; 1993:546-580.
58. u variant mother. Transfusion. 1982;22:76-77.
59. Gorman JG. New applications of Rh immune globulin: effect on protocols. In: Frigoletto FD, Jewett JF, Konugres AA, eds. Rh Hemolytic Disease: New Strategy for Eradication. Boston, Mass: GK Hall Medical Publishers, 1981:199-210.
60. Mayne KM, Allen DL, Bowell PJ. "Partial D" women with anti-D alloimmunization in pregnancy. Clin Lab Haematol. 1991;13:239-244.
61. u patient. J Lab Clin Med. 1953;41:895-898.
62. u variant woman. Vox Sang. 1978; 34:40-42.
63. u incompatibility in a newborn with high levels of anti-D and a benign clinical course. Vox Sang. 1986;50:52-53.
64. Østgard P, Fevang F, Kornstad L. Anti-D in a "D positive" mother giving rise to severe haemolytic disease of the newborn. Acta Paediatr Scand. 1986;75:175-178.
65. Va. Br J Haematol. 1990;76:537-539.
66. u variant mother. Transfusion. 1983;23:91-94.
67. u-positive women: a cause of hemolytic disease of the newborn. Am J Obstet Gynecol. 1983;145:1069-1075.
68. Filbey D, Berseus O, Carlberg M. Occurrence of anti-D in RhD-positive mothers and the outcome of the newborns. Acta Obstet Gynecol Scand. 1996;75:585-587.
69. Lubenko A, Contreras M, Habash J. Should anti-Rh immunoglobulin be given to D variant women? Br J Haemotol. 1989;72:429-433.
70. Davey RJ, McMican A, eds. Collected Questions and Answers. 4th ed. Bethesda, Md: American Association of Blood Banks; 1994:29.
71. Schmidt PJ, Pautler K, Samia CT. Prenatal Rh typing errors. Am J Obstet Gynecol. 1983;145:884-885.
72. Sebring ES, Polesky HF. Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects. Transfusion. 1990;30:344-357.
73. Ness PM, Baldwin ML, Niebyl JR. Clinical high-risk designation does not predict excess fetal-maternal hemorrhage. Am J Obstet Gynecol 1987;156:154-158.
74. Nicolaides KH, Clewell WH, Rodeck CH. Measurement of human fetoplacental blood volume in erythroblastosis fetalis. Am J Obstet Gynecol. 1987;157:50-53.
75. 2 indicator erythrocytes. Transfusion. 1982;22:468-471.
76. o hemolytic disease of the newborn: the rosette method: a rapid, sensitive screening test. Mayo Clin Proc. 1983;58:342-343.
77. Riley JZ, Ness PM, Taddie SJ, et al. Detection and quantitation of fetal maternal hemorrhage utilizing an enzyme-linked antiglobulin test. Transfusion. 1982;22:472-174.
78. Ness PM, Riley JZ. The detection of feto-maternal hemorrhage by enzyme-linked antiglobulin test (ELAT). In: Frigoletto FD, Jewett JF, Konugres AA, eds. Rh Hemolytic Disease: New Strategy for Eradication. Boston, Mass: GK Hall Medical Publishers; 1981:135-142.
79. Patton WN, Nicholson GS, Sawers AH, et al. Assessment of fetal-maternal haemorrhage in mothers with hereditary persistence of fetal haemoglobin. J Clin Pathol. 1990; 43:728-731.
80. Nelson M, Popp H, Horky K, et al. Development of a flow cytometric test for the detection of D-positive fetal cells after fetomaternal hemorrhage and a survey of the prevalence in D-negative women. Immunohematology. 1994;10:55-59.
81. Corsetti JP, Cox C, Leary JF, et al. Comparison of quantitative acid-elution technique and flow cytometry for detecting fetomaternal hemorrhage. Ann Clin Lab Sci. 1987;17: 197-206.
82. Johnson PRE, Tait RC, Austin EB, et al. Flow cytometry in diagnosis and management of large fetomaternal haemorrhage. J Clin Pathol 1995;48:1005-1008.
83. Kleihauer E, Braun H, Betke K. Demonstration von fetalem Hämoglobin in den Erythrocyten eines Blutausstrichs. Klin Wochenschr. 1957;35:637-638.
84. Polesky HF, Sebring ES. Evaluation of methods for detection and quantitation of fetal cells and their effect on RhIgG usage. Am J Clin Pathol. 1981;76:525-529.
85. Bayliss KM, Kueck BD, Johnson ST, et al. Detecting fetomaternal hemorrhage: a comparison of five methods. Transfusion. 1991;31:1303-1307.
86. Pembrey ME, Weatherall DJ, Clegg JB. Maternal synthesis of hemoglobin F in pregnancy. Lancet. 1973;1:1350-1354.
87. Turner WA, Fadel HE, Krauss JS. Detection and quantitation of fetomaternal hemorrhage. South Med J. 1986;79:571-575.
88. Duerbeck NB, Seeds JW. Rhesus immunization in pregnancy: a review. Obstet Gynecol Surv. 1993;48:801-810.
89. Ness PM, Salamon JL. The failure of postinjection Rh immune globulin titers to detect large fetal-maternal hemorrhages. Am J Clin Pathol. 1986;85:604-606.
90. Davey RJ, McMican A, Widmann FK, et al, eds. Collected Questions and Answers. 3rd ed. Arlington, Va: American Association of Blood Banks; 1991:57-58.